KEY TAKEAWAYS
- The study aimed to use FA-ZIF-90 to enhance cisplatin delivery, overcome resistance, and improve clinical outcomes in OC.
- Researchers noticed that FA-ZIF-90 enhanced drug targeting, anti-tumor effects, and reversed resistance in OC.
Tolerance to chemotherapeutic agents is commonly acquired in ovarian cancer (OC) cells, which adversely affects clinical outcomes. Novel strategies to target enhancing the response of chemotherapeutic agents to overcome drug resistance and minimize side effects are significant for improving the clinical outcomes of patients (pts) with OC.
Yan Xing and the team aimed to develop novel strategies using folic acid (FA)-modified ZIF-90 nanomaterials (FA-ZIF-90) to enhance the targeting and delivery of cisplatin, overcome drug resistance in OC cells, and enhance clinical outcomes.
Researchers employed FA-ZIF-90 to deliver the chemotherapeutic drug cisplatin (DDP) via dual targeting to improve its targeting and circumvent cisplatin resistance in OC cells, especially by targeting mitochondria. FA-ZIF-90/DDP could rapidly release DDP in response to dual stimulation of acidity and ATP in tumor cells.
They found that the FA-ZIF-90/DDP demonstrated good compatibility with blood and was efficiently taken up by human OC cisplatin-resistant cells A2780/DDP, accumulating in the mitochondrial region. This formulation demonstrated statistically significant inhibition of mitochondrial activity and the metastatic ability of A2780/DDP cells.
Further, FA-ZIF-90/DDP effectively induced apoptosis in these cells, overcoming cisplatin resistance. In vivo experiments further confirmed the efficacy of FA-ZIF-90/DDP, demonstrating the increased accumulation of DDP in tumor tissues and significant inhibition of tumor growth.
The study concluded that FA-ZIF-90 enhanced drug targeting, anti-tumor effects, and reversed resistance in OC.
The study was funded by the National Natural Science Foundation of China (32101153) and the Zhejiang Medical Health Science and Technology Project (2023KY264, 2024KY325).
Source: https://pubmed.ncbi.nlm.nih.gov/38979533/
Xing Y, Jing R, Tang X, et al. (2024). “Dual-Targeted Zeolitic Imidazolate Frameworks Drug Delivery System Reversing Cisplatin Resistance to Treat Resistant Ovarian Cancer.” Int J Nanomedicine. 2024 Jul 3;19:6603-6618. doi: 10.2147/IJN.S434950. PMID: 38979533; PMCID: PMC11230133.
